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Diagnosis of human immunodeficiency virus (HIV) infections has relied most frequently on
detecting the presence of HIV antibodies in sera. In many situations, however, patient manage-
ment can be significantly improved if the presence of HIV can be demonstrated in patients'
specimens. In this review, the need and value of HIV isolation for confirming the diagnosis of
HIV, for disease staging, and for monitoring the effectiveness ofantiviral therapy are discussed.
The steps involved in isolation of HIV, the cell systems permissive to HIV growth, and the
procedures for virus identification are reviewed. Furthermore, methods available for the direct
detection of HIV in patients' specimens are summarized. Although isolation of HIV is presently
an elaborate procedure, as easier methods become available, it will play a large role in the
management of HIV-infected individuals.
INTRODUCTION
The recent emergence of the acquired immune deficiency syndrome (AIDS) has
profoundly challenged medical practitioners. But virologists in particular have been
compelled to confront the challenge, since the etiologic agent has been identified as a
retrovirus now called the human immunodeficiency virus (HIV). During the past five
years, substantial progress has been made in understanding the molecular biology and
pathogenesis of this virus. An important advance has been the establishment of
laboratory methods for detecting the presence of HIV and antibodies to HIV. Because
of the obvious public health significance, emphasis has been placed on procedures to
screen blood and blood products for the presence of HIV antibodies.
While serodiagnosis is now used routinely for demonstrating exposure to HIV, none
of the tests currently used is able to differentiate perfectly between infected and
uninfected individuals. Isolation of HIV from clinical specimens is less frequently
attempted and is performed primarily in specialized research centers. The inherent
value of isolation and identification of HIV has been underestimated, despite the fact
that there is a clear need for a test, not dependent on antibody detection, to confirm
that a person is infected with HIV.
In this paper, the indications for useofHIV isolation in the laboratory are discussed.
The principles of the procedures used for isolating and identifying HIV are outlined,
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TABLE 1
Indications for Isolation and Direct Detection of HIV
1. Confirmation ofdiagnosis of HIV infection
a. Detection ofHIV infection in individuals who have no detectable antibodies
* because ofrecent acquisition ofinfection
* because ofsevere immunosuppression
b. Confirmation of HIV infection in cases where the significance ofseropositivity
is unclear
* in infants born to HIV-infected mothers
* in individuals with equivocal Western blot results
2. Disease staging
a. Monitoring ofasymptomatic antibody-positive individuals for the presence of
HIV in blood
b. Assessment ofpresence of HIV in cerebrospinal fluid in patients with central
nervous system disease
3. Evaluation ofeffectiveness ofantiviral therapy
and the host systems available forvirus isolation are reviewed. Inaddition, the methods
used for direct detection ofthe virus in clinical specimens are discussed.
VALUE AND INDICATIONS OF HIV IDENTIFICATION
IN THE LABORATORY
There are situations where isolation of HIV in the laboratory is not a luxury but is
instead mandated because such information facilitates proper management of HIV-
infected patients (Table 1).
Confirmation ofDiagnosis
HIV isolation may serve todetect HIV infection in antibody-negative individuals. In
recently acquired HIV infection, infectious virus and HIV antigen may be present
early, without detectable antibody [1,2]. Allain et al. [2] found in a study of
hemophiliacs that the sequence of early markers of HIV infection were first HIV
antigens, then antibodies to envelope proteins, and finally antibodies to core proteins.
Antigenemia could be detected as early as two weeks after infection, whereas
antibodies were not detectable until one month later [2]. Thus, demonstration of the
presence of HIV may serve to detect early primary HIV infection and may allow the
identification ofantibody-negative individuals who are infectious. Antibody levels may
decline to very low or undetectable levels in symptomatic or asymptomatic patients
with HIV infections of longer duration. In these cases, identification of HIV in the
patient's blood or other specimens may serve to define the sites involved in the
infection.
HIV isolation can be used to confirm the diagnosis of HIV infection in infants who
are born to HIV-infected mothers. Since newborns are not fullyimmunocompetent and
because maternal antibodies cross the placenta, serologic methods are less useful as a
means ofrapidly detecting HIV infection in a newborn. Culture or direct detection of
HIV may also be helpful in clarifying equivocal or negative Western blot results in an
individual seropositive when tested by the enzyme-linked immunosorbent assay.
Disease Staging
Monitoring ofasymptomatic antibody-positive patients for the presenceofHIV may
serve to predict a progression to active disease. HIV antigenemia, accompanied by a
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disappearance ofantibody reactivity to the major HIV core protein p24, was found to
precede the onset of AIDS in one adult and five children who were antibody-positive
[3]. HIV culturing from cerebrospinal fluid may be useful to demonstrate active HIV
infection in the brain of patients who develop central nervous system disease. In
addition, the persistence or reappearance of HIV antigens in blood and cerebrospinal
fluid has been found to correlate with clinical, immunological, and neurological
deterioration [1].
Evaluation ofEffectiveness ofAntiviral Therapy
As promising antiviral chemotherapy becomes available, early recognition ofactive
HIV infection in patients will permit institution oftherapy early during the course of
the disease and, it is hoped, will optimize effectiveness. Monitoring oftreated patients
for the presence ofinfectious virus is mandatory to monitor accurately effectiveness of
antiviral compounds. Evaluation of the effectiveness of antiviral therapy depends
crucially on the ability to quantify changes in HIV concentrations in specimens of
treated patients. Presently, a positive blood culture is usually required for entry into
clinical trials ofanti-HIV therapy, and the effectiveness ofdrug treatment is evaluated
by monitoring blood throughout therapy for changes in virus concentration [4].
VIRUS ISOLATION
Two observations have greatly facilitated the development of procedures for
isolation ofHIV. First, thediscovery ofT-cell growth factors for the continuous growth
ofhuman T cells in vitro [5,6]. Second, the observation that HIV can be propagated in
human peripheral mononuclear cells [7-9]. In first reports, HIV was directly isolated
from peripheral blood, bone marrow, or lymph node mononuclear cells obtained from
AIDS patients and placed in cultures [7,8,10-12]. Subsequently, isolation of HIV was
successfully accomplished when patients' specimens were inoculated in lymphocyte
cultures obtained from normal human blood or umbilical cord blood [7,8,10,13] or in
permissive T-cell lines [8,10,12]. Sites from which HIV has been isolated are listed on
Table 2.
At present, isolation of HIV is an elaborate and labor-intensive procedure. The
various steps involved in the isolation and identification of HIV, using fresh lympho-
cytes from normal donors, are outlined in Fig. 1. To prepare cultures of human
lymphocytes from fresh peripheral blood of normal donors, mononuclear cells are
obtained by Ficoll-Hypaque centrifugation and suspended in culture media containing
a mitogen such as phytohemagglutinin and a T-cell growth factor such as interleukin-
577578 BRIGITTE P. GRIFFITH
Clinical specimen: Fresh normal donor's lymphocytes
body fluids or ficoll hypaque (stimulated and cultured)
separated peripheral blood
mononuclear cells \ v
2-4 weeks in culture
Infected cells release virus - Subculture by transfer
in the supernatant to fresh normal donor's
lymphocytes
(stimulated and cultured)
Weekly identification of virus
in
cells supernatants
viral ~ viral viral
antigen particles viral genome
(IFA) (electron microscopy) enzyme (dot-blot hybridization)
[ reverse 1
viral transcriptase
genome assay FIG. 1. Flow chart for iso-
(dot-blot or in situ hybridization) viral FiG. 1. Flow fcatfor o-
antigen lation and identification of
(ELISA,RIA) HIV.
2. Cultures of normal donor lymphocytes can be inoculated with patients' specimens
within three to four days after initiation of the cultures. At the time of specimen
inoculation, the stimulated normal lymphocytes are treated with polybrene or DEAE
Dextran to facilitate virus absorption [14]. It has also been suggested that addition of
antibody to human a interferon to culture media increases the ability to recover HIV
from in vitro cultures [7]. This antiserum neutralizes endogenous interferon, which is
secreted by cells chronically infected by viruses-including retroviruses. The normal
donor cell cultures inoculated with the clinical specimens are kept in culture for three
to four weeks. They are monitored biweekly for cell counts and viability by the trypan
blue exclusion method or by measuring 3H thymidine uptake [15]. Tissue culture
media are replaced with fresh media twice weekly and freshly prepared stimulated
lymphocyte cultures from normal donors are added once a week.
Depending on the amount of virus present in the patient's specimen, infected cells
will show, to various degrees, a characteristic cytopathic effect (CPE) consisting of
multinucleated giant cells with ring formation. These multinucleated giant cells
produce large amounts of virus and die over a period of a few days. As infection
spreads, infected cells can be seen at all stagesofdevelopment. In theearly phase, giant
cells have a clear, bubble-like cytoplasm that projects from the edges of clusters of
growing lymphocytes. Subsequently, cell fusion occurs and numerous multinucleated
giant cells, which are often masked by clusters of proliferating lymphocytes, are
present. As CPE progresses, thecytoplasm is reduced and becomes granular before the
cells disintegrate. A minor cell population may survive and give rise to another burst of
virus production, followed again by cell death. Examples of CPE patterns seen in H9
cells infected with HIV are shown in Fig. 2.
In addition to evaluation of cell viability and cytopathology, the cell cultures are
monitored at weekly intervals throughout the culture for virus expression and release
(Fig. 1). One or more ofthe following assays can be utilized to identify the presence of
HIV in supernatants of the lymphocyte cultures: (1) assay of particulate reverse
transcriptase activity; (2) detection of HIV antigens by enzyme-linked immunosorbent
assays or radioimmunosassays; (3) detection ofviral genome by nucleic acid hybridiza-DETECTION OF HUMAN IMMUNODEFICIENCY VIRUS
FIG. 2. Cytopathic changes in H9 cells, seven days post-inoculation with HIV (strain




Cells Frequently Used for HIV Growth
Cytopathic
Cell Type Cell Line Effecta HIV Production References
Normal Donor Cells Blood lymphocytes + + + + Transient [7,11]
Umbilical cord lympho- + + + + Transient [7,8,13]
cytes
Monocytes, macrophages + + Continuous [17,18]
Neoplastic T-Cell Lines HT + + Continuous [8,10,21]
H9 + + Continuous [8,10,21]
Hut 78 + + Continuous [9,10,12,21]
Molt 3 + + + + Continuous [21]
Molt 4 + + + + Continuous [20]
CCRF-CEM + + Continuous [19,20,211
A 3.01 + + + + Transientb [15]
MT2c + + + + Plaque formation [25-27]
MT4c + + + + Plaque formation [25-27]
Monocytic Cell Lines U937 + + Continuous [16,20]
'Plus signs indicate extent ofcytopathic effect: + + + + extensive, + + limited
bWith possible reactivation
cThese cell lines carry HTLV I.
tion. Infected cells can also be evaluated for (1) the presence of HIV antigen by an
indirect immunofluorescence assay; (2) the presence of viral genome by nucleic acid
hybridization; (3) the presence of viral particles by electron microscopy. To further
confirm the presence of HIV in the clinical specimen, subculture ofthe newly isolated
virus to uninfected cell cultures can be performed and the isolated virus identified as
described above.
HOST CELL SUSCEPTIBILITY
As with other viruses, the availability ofsusceptible cells is crucial for the successful
isolation of HIV. The first recognition ofthe presence of HIV was based on its in vitro
toxic and cytopathic effect on T helper cells from patients with AIDS or at risk for
AIDS [7-9]. The major target of HIV has been demonstrated to be T4 cells [11,16]
and cultures ofT helper cells prepared from blood, bone marrow, and lymph node have
grown HIV [8,10-12]; however, short-term cultures ofmonocytes/macrophages and B
lymphocytes can also be infected with HIV [17-20].
The types which have been frequently used for HIV growth are listed in Table 3. In
addition to cultures prepared from normal human peripheral blood mononuclear cells
or umbilical cord lymphocytes, neoplastic T-cell lines and some macrophage cell lines
can efficiently propagate HIV in vitro. While some neoplastic B-cell lines have been
found to be permissive to HIV [19,20,23], they have not been used for HIV growth.
Transmission of HIV to an established T-cell line, H9, was first achieved by Popovic et
al. [10]. In addition to this cell line, a number of other T-cell lines have been found to
be susceptible to HIV [11,16,21,22]. In contrast to freshly prepared short-term
lymphocyte cultures derived from normal donors, cells from neoplastic lines have the
advantage that, when chronically infected, they continue to grow, show little CPE, and
produce large amounts of virus [9,12,20,21]. These neoplastic T-cell lines express the
T4 cell surface marker which is believed to be associated with susceptibility to the
580DETECTION OF HUMAN IMMUNODEFICIENCY VIRUS
virus. Because differences in T helper cell antigen expression in established cell lines
have been obtained in various laboratories, differences in susceptibility of some cell
lines to HIV, for example, the Molt 4 cell line, have been noted [10,20].
Primary cultures prepared from normal donors have been reported to be more
sensitive than neoplastic T-cell lines for the isolation of HIV from patients' specimens
[24]. Virus is produced earlier during the course of the in vitro infection, and the
amount ofvirus released is often higher in freshly prepared lymphocyte cultures than
in established cell lines. Attempts atdeveloping sensitive and useful cell lines have been
made. One cell line cloned from the CEM cell line was found to mimic primary
lymphocyte cultures from normal donors in that virus production was transient and
CPE was seen as early as three to five days after infection and resulted in significant
cytotoxicity [15]; however, this cell line was less sensitive to infection by HIV than
normal mononuclear cell cultures [15]. A variety of other cell lines have been tested
without success [20]. Plaque assays which are used to quantitate virus infectivity
cannot be readily performed in cells that grow in suspension. Therefore, two neoplastic
T-cell lines (MT2 and MT4) that carry the HTLV I genome and grow in monolayers
have been used in a plaque assay developed by Harada et al. [25-27].
METHODS OF VIRUS IDENTIFICATION
Methods ofHIV identification rely frequently on the demonstration ofviral proteins
in infected cells or in supernatants of infected cells.
Detection ofReverse Transcriptase Activity in Supernatants ofInfected Cells
The measurement ofreverse transcriptase is broadly utilized as the primary method
for the detection and quantitation of HIV infectivity. The assay is based on identifying
the enzyme's capacity to assemble DNA from a RNA template. In general, it takes 7
to 21 days of co-cultivation of HIV-infected specimens with susceptible cells to
accumulate adequate virus for detectability in the supernatant.
The following steps take place during the reverse transcriptase assay. Virus is
precipitated from cell-free supernatant by polyethylene glycol. The pellet containing
virus is then disrupted by a detergent. The disrupted virus is mixed with 3H-labeled
deoxythymidine triphosphate, MgCl2, a primer, and either of two synthetic templates,
polyribo(A) and polydeoxyribo(A). The reaction takes place at 370C for one hour. The
two templates used allow for the distinction between the viral reverse transcriptase that
uses RNA as a template and the activity of related cellular polymerases that exploit
DNA as a template. The labeled DNA synthesized by the reverse transcriptase is
precipitated by trichloracetic acid and the amount of incorporated radioactivity is
determined by scintillation counting. A combination ofgood response with polyribo(A)
and a poor response with polydeoxyribo(A) is indicative of viral reverse transcriptase
activity.
Detection ofHIVAntigens in Supernatants ofInfected Cells
Because the protocols for sample pretreatment and for measurement of the reverse
transcriptase are cumbersome and labor-intensive, and because the assay is not specific
for HIV, a number of methods have been developed to measure more efficiently and
specifically virus release in supernatants of cell cultures. Radioimmunoassays (RIA)
and enzyme-linked immunosorbent assays (ELISA) have been utilized and are both
based on the immunological detection of the p24 major structural HIV core protein.
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The principle of the RIA test is based on the competition between a radioactive and
non-radioactive antigen for a fixed number ofantibody binding sites. The precipitation
of'25I-labeled affinity purified p24 by a reference monospecific rabbit polyclonal
antiserum iscompeted with clinical samples containing unlabeled HIV antigen. In the
antigencapture sandwich ELISA, polyclonal antibodies [28] or monoclonal antibodies
that recognize epitopes of the HIV core protein [29] are coated to beads or plates and
used to catch the antigen. A positive reaction is identified with a probe anti-HIV
antibody and a labeled secondary antibody. The capture ELISA has been found to
compare well with the reverse transcriptase assay and requires twentyfold less
supernatant material [28,29]. In addition, the ELISA and RIA for the viral core
protein were more sensitive than the reversetranscriptase in detecting HIV in dilutions
ofchronically infected H9 cultures and allowed for the detection of HIV in superna-
tant of H9 and PHA-stimulated peripheral blood leukocytes earlier during the course
of the infection [30].
Detection ofHIVAntigens in Infected Cells
The presence of HIV antigens in cultured cells can be demonstrated rapidly by an
indirect immunofluorescence assay (IFA). Cells from HIV-infected cultures and
control uninfected cells are placed on welled slides and fixed. They are reacted with a
primary HIV-positive antiserum. Aprimary HIV-negative serum is used as control. A
fluorescein-labeled antihuman IgG antibody is used as the secondary antiserum. The
assay is simple to perform but needs to be controlled carefully because cells used as
target containmanyantigens thatmightpossibly react nonspecifically with antibodies.
Forexample, classII histocompatibility DR proteins have been identified in prepara-
tions of HIV made in H9 cells and represent a ready source ofantigen which can cause
false-positive reactions [31]. IFA has been used to monitor HIV infection in a number
ofneoplastic T-cell lines including CEM, H9, and Hut 78 [32-34]. In H9 cells, three
patterns of HIV-specific reactivity have been observed: a peripheral pattern seen
frequentlyduringearlylogphase, a starpattern, and a clumped pattern dominating in
cells fixed in late log phase of replication [33]. In HIV-infected Hut 78 cells, two
different staining patterns were observed: a diffuse cytoplasmic pattern and a
cytoplasmic focal pattern [34].
Detection ofHIVNucleic Acids in Supernatants of/or in Infected Cells
Various methods based on the detection of HIV nucleic acids have been used as a
means to identify HIV. A cytoplasmic dot-blot technique has also been developed to
detect viral RNA sequences in infected cultured cells [35]. In this assay, cytoplasmic
RNAprepared from cultured cells is denatured, spotted on nylon filters, and detected
with a32P-labeled DNA clone of HIV. When compared to the reverse transcriptase
assay and IFA, the RNA dot-blot method allowed for the detection of HIV several
days earlier during the course of the infection. A procedure using 2-acetylaminofluo-
rene (AAF)-modified DNA as hybridization probe for HIV nucleic acids spotted on
nitrocellulose filters has also been utilized [36]. AAF was used to covalently modify
guanine residues in a 6.5 kb fragment of cloned HIV DNA. Rabbit antibody to AAF
was added and the AAF-DNA antibody complex was detected with a fluorescein or
alkaline phosphatase tagged secondary antibody [36]. A recently developed oligonu-
cleotide-directed procedure which provided a 105-fold in vitro amplification of DNA
templates could identify infected cell lines that were not actively releasing virus
particles asjudged by absence ofreverse transcriptase activity [37].
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Detection ofViral Particles by Electron Microscopy
Electron microscopy does not play a large role in the identification of HIV isolates
despite the fact that it allows for the direct detection of HIV in infected cells and that
the ultrastructure of HIV is significantly different from that of other retroviruses.
Studies of the ultrastructural development of HIV have indicated that most virus is
found in extracellular spaces and that cytoplasmic inclusions or nucleocapsid precur-
sors are usually not detected [38,39]. Figure 3 shows typical HIV particles as seen
under the electron microscope.
DIRECT DETECTION OF HIV ANTIGENS OR GENOME
IN CLINICAL SAMPLES
Methods for detecting HIV directly in body fluids and cells from infected individu-
als do not involve prior in vitro amplification in cell cultures and thus are rapid and less
cumbersome, but also less sensitive. The previously described sandwich ELISA for
detecting HIV core antigen in supernatants ofcultured cells has been utilized to detect
HIV antigen in serum and cerebrospinal fluid [1-3]. Antigenemia was found to
precede the onset ofAIDS [3] and could be demonstrated as early as two weeks after
infection, one month prior to the appearance of HIV antibodies [2]. In patients
enrolled in a placebo controlled trial ofazidothymidine, a significant decrease in HIV
core antigen was demonstrated in the serum of patients treated with azidothymidine,
as compared to placebo-treated controls [4]. Direct detection of HIV antigen
expressed in vivo on the surface of human lymphocytes has also been accomplished
with monoclonal anti-HIV antibodies using a flow cytometer [40].
Immunological reagents directed to viral antigens may not permit detection of the
virus during some stages ofdisease, particularly during persistent infection when only
small quantities of virus particles may be actively produced. A strategy for viral
detection in this case would require the identification ofviral nucleic acids in infected
cells. Techniques for detecting HIV nucleic acids in infected individuals have been
developed in a number of laboratories. HIV infection was demonstrated in mononu-
clear cells ofa newborn by insitu hybridization with a HIV-specific cDNA probe [41].
Harper et al. utilized 35S-labeled HIV-specific RNA probes to detect lymphocytes
expressing HIV in lymph nodes and blood from infected individuals by in situ
hybridization [42]. In another report, HIV RNA was detected in peripheral blood
mononuclear cells by hybridization on nitrocellulose filters, using probes prepared
from proviral DNA and labeled with 32p [43]. Results obtained from these studies all
clearly suggest that, in uncultured lymph nodes or peripheral blood cells from infected
individuals, only very few lymphocytes express HIV RNA.
CONCLUSION
Since the initial reports of AIDS cases over five years ago, much effort has been
expended in attempts to improve methods for the diagnosis of HIV infection. Over the
next decade, with the expected progress in antiviral therapy and knowledge of the
disease, the need for an accurate and rapiddiagnosis ofHIV infection willundoubtedly
become more acute. Currently, HIV isolation remains a time-consuming and cumber-
someprocedure. Although significant improvement in methodsofdirect HIVdetection
has been made, it appears that only a very small number of cells are infected in vivo.
Therefore, culture of HIV in permissive cells, which results in amplification of initial
virus input, is likely to continue to play a crucial role in diagnosis of HIV in the
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FIG. 3. Electron micrograph of an HIV-infected H9 cell, ten days post-inoculation with HIV (strain
HTLV-IIIB). Typical HIV particles are seen in extracellular spaces (bar represents 0.5 g). Insert shows
detail of HIV particles (bar represents 0.2 IA).
laboratory. To arrive at an accurate identification of HIV, results obtained need to be
interpreted carefully in light of the specimen, the cell system, and the methods used.
Some of the neoplastic cell lines that contain endogenous retroviruses may yield
mixtures of HIV and other HTLV types. Other retroviruses such as the human
retrovirus associated with adult T-cell leukemia virus also show syncytia formation
[44], and dual infections with human T-cell leukemia virus and HIV have been
reported [45,46]. In addition, tests used commonly to identify HIV, such as the reverse
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transcriptase assay, are not specific for HIV, since other retroviruses also yield reverse
transcriptase activity. The virus isolation process may also be further complicated by
differences in the replicative ability of different clinical isolates [12,13,20,47,48].
Furthermore, some cases of AIDS have been found to be caused by other biotypes of
HIV [49-51]. These newly isolated viruses differ in some of their antigenic and
genomic characteristics from previous HIV isolates but have similar growth and
cytopathic properties. As more is learned about HIV-cell interactions in vitro, the
development of less elaborate procedures for HIV isolation can be anticipated.
Undoubtedly, this will result eventually in the incorporation of HIV isolation and
identification methodology into the repertoire ofmany clinical virology laboratories.
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